Mendelian randomisation analysis has emerged as an important tool to elucidate the causal relevance of a range of environmental and biological risk factors for human disease. However, inference on cause is undermined if the genetic variants used to instrument a risk factor of interest also associate with other traits that open alternative pathways to the disease (horizontal pleiotropy). We show how the 'no horizontal pleiotropy assumption' in MR analysis is strengthened when proteins are the risk factors of interest. Proteins are the proximal effectors of biological processes encoded in the genome, and are becoming assayable on an -omics scale.
Introduction
Mendelian randomization (MR) studies estimate the causal relationship of a risk factor of biomedical interest to disease outcomes using genetic variants as instruments to index the risk factor 1 . The naturally randomised allocation of genetic variation at conception reduces the potential for confounding, which compromises causal inference drawn from the directly observed association between risk factor and disease 2 .
Risk factors of biomedical interest (some of which are amenable to modification by drugs or behaviour change) can be both exogenous and endogenous, encompassing health-related behaviours (e.g. smoking and alcohol consumption 3 ), complex biological traits (e.g. blood pressure and body mass index 4 ) or, circulating constituents of the blood (e.g. complex analytes such as lipoproteins, metabolites such as uric acid 5 , or proteins such as interleukin-6 6, 7 , hundreds or thousands of which can now be assayed on high throughput platforms, e.g. from Somalogic and O-Link 8 ). Interest has also emerged in tissue-level mRNA expression as an exposure of interest 9 .
Four advances have fuelled an explosion in MR studies. First, genome-wide association studies (GWAS) have provided a rich source of genetic instruments 10 . Second, access to summary level genome wide association data has been made possible through the provision of public data repositories 11 . Third, methods have been developed to execute two-sample MR analysis (risk factor vs disease outcome) based on summary level genetic associations, obviating the need to share potentially sensitive participant information 12 . Fourth, bioinformatics tools have been developed that allow efficient exploitation of such resources. For example, MR-base 13 is an online platform for MR analyses that links summary level genetic estimates with a number of analytic tools. Additional resources that can be utilised include GCTA, PrediXcan 14 and MetaXcan 15 .
Most prior MR analyses utilise an approach whereby multiple SNPs identified from GWAS are used as instruments to increase power. SNPs are drawn from throughout the genome, often with a single variant selected per locus 16 ensuring instruments are independent (i.e. in linkage equilibrium); preventing erroneously inflated statistical significance. This standard approach has often been applied regardless of the position of the exposure of interest in the biological pathway connecting genetic variation to disease risk. For example, an MR analysis investigating the causal relevance of C-reactive protein in a range of disease end-points 17 , and another between educational attainment on cardiovascular disease risk were conducted using broadly similar methodology and assumptions 18 .
However, there are reasons for thinking that MR analysis of a protein risk factor should be considered as a distinct category of MR analysis. First, an analysis of this type induces a natural dichotomy in the genetic instruments that might be used: those that are located in and around the encoding gene ('cis-MR') vs those located elsewhere in the genome (trans-MR) 19 . Second, aside from mRNA expression, differences in protein expression or function are the most proximal consequence of natural genetic variation. This has two consequences: frequently, variants located in and around the encoding gene can be identified with a very substantial effect on protein expression in comparison to other traits; moreover such instruments may also be less to prone to violating the 'no horizontal pleiotropy' assumption' than variants located elsewhere in the genome (discussed below and ref 19 ). Lastly, in the case of MR analysis of proteins, Crick's 'Central Dogma' 20 imposes an order on the direction of information flow from gene to mRNA to encoded protein, which does not extend beyond this to other biological traits that lie more distally in the causal chain that connects genetic variation to disease risk. Thus, from an MR perspective, proteins are in a privileged position compared to other categories of risk factor.
Understanding which proteins influence which diseases is a fundamental problem in biomedical science since proteins are the major biological effector molecules. Proteins are also the targets of most medicines, so interest has emerged in the use of MR approaches to identify and validate drug targets [21] [22] [23] [24] . Moreover, recent technological developments enable measurement of hundreds or thousands of proteins on an -omics scale in a single biological sample 8 . This opens up the possibility of scaled cis-MR analysis of thousands of proteins against hundreds of diseases to inform understanding of their causes and improve drug development yield.
The key to realising this potential is the development of a robust conceptual and mathematical framework for cis-MR analysis of proteins. Since cis-MR analysis restricts selection of genetic instruments to those located in, or in the vicinity of the encoding gene, new questions emerge as how to optimise the selection of such variants. These include how best to select and define the loci of interest, the physical distance around each gene from which instruments might be drawn;
how to select genetic variants as instruments with options including "no selection", "selection by strength of association", or "according to functional annotation. Regulatory, non-coding variants act through the level of the encoded protein which is what high-throughput assays detect.
Coding-variants might influence protein activity but may also alter the detected rather than actual protein level by protein epitope changes, resulting in a technical artefact. Further questions include whether to weight such instruments in an MR analysis by the level of protein expression or activity, where the relevant assays are available; or, where they are not, by the level of mRNA expression (and, if so, in which tissue), or by some downstream consequence of protein action, e.g. differences in the level of a metabolite known to be influenced by the protein.
We therefore develop a mathematical framework for cis-MR analysis for causal understanding and drug development and investigate the influence of alternative strategies for the selection of genetic instruments and the choice of analytical approach best suited to this task; agnostic of the type of estimation methods.
To help validate our findings, we select examples where the effect of a drug has already been reliably quantified on the protein of interest; on a widely measured downstream mediator of its effect; and on the disease outcome for which the treatment is indicated; and where variants in the gene encoding the drug target have been associated with effects that are consistent with this knowledge. Four genes that fulfil these criteria are HMGCR, PCSK9, NPC1L1 and CETP that encode the targets of licensed or clinical phase drugs with known effects on lipids and coronary heart disease risk.
A mathematical framework for cis-MR analysis MR studies determine the causal effect of a risk factor on a disease using instrumental variable (IV) methods 25 , leveraging two estimates: the genetic association with the risk factor (exposure) and the genetic association with the disease (outcome). For the effect estimate in MR to equate to a causal estimate the following critical assumptions should hold: (i) the genetic instrument is (strongly) associated with the exposure, (ii) the genetic instrument is independent of observed and unobserved confounders of the exposure-outcome association (which is secure because genetic variants are fixed and allocated at random), and (iii) conditional on the exposure and confounders, the genetic instrument is independent of the outcome (i.e. there is no instrumentoutcome effect other than through the exposure of interest -the "no horizontal pleiotropy" assumption).
The no horizontal pleiotropy assumption is violated when there are additional pathways by which the instrument may be related to the disease, sidestepping the exposure of interest. This could occur, for example if a genetic variant is in linkage disequilibrium (LD) with another variant that influences disease through a pathway distinct from the exposure, or if a genetic instrument also influences disease risk through another risk factor, located proximal to the risk factor of interest in the causal chain from gene to disease. In contrast, the association of a genetic instrument with exposures that lie in the causal chain distal to the exposure of interest (vertical pleiotropy 26 ) does not violate the assumptions underpinning MR analysis. In the context of MR analysis of proteins, vertical and horizontal pleiotropy correspond to 'pre-' and 'post'-translational effects respectively.
To address the possibility of horizontal pleiotropy in MR analyses of exposures other than proteins, it has been common to select as instruments independently inherited SNPs identified by GWAS from multiple locations across the genome. In doing so, the average horizontal pleiotropy may reduce to zero (so-called balanced pleiotropy). Where this is not the case, an estimator such as MR-Egger 27 can recover an estimate of the causal effect in the presence of horizontal pleiotropy contingent on the Instrument Strength is Independent of the Direct Effect (INSIDE) assumption 27 ; i.e., that the strength of the genetic association with the risk factor does not determine the magnitude of horizontal pleiotropy.. Figure 1 adapts the typical depiction of an MR analysis to illustrate these considerations. A genetic variant ( ) has the potential to influence risk of disease (D) directly ( ) or through its effect ( ) on a protein (P) which exerts its action through a downstream biomarker (X), which in turn influences disease risk. The relevant genetic associations can be resolved as follows:
1) The genetic effect on the protein .
2) The genetic effect on a downstream complex biomarker . Depending on the risk factor of interest, an MR analysis constitutes a simple quotient of the genetic effect on disease by the genetic effect on the risk factor. For example, if we are interested in the causal effect the biomarker X on disease, i.e. , we use the following ratio.
.
For expression (1) to equate to the causal effect on disease we need to additionally assume that there is no horizontal pleiotropy, in other words = = 0, which reduces the expression to:
In contrast, if we are interested in the causal effect of the protein P on disease D, we want to obtain an estimate of , where = + , we assume = 0 as before, and use the ratio:
= .
Critically, where the causal effect of the protein is the parameter of interest, we only need to assume that there is no direct effect of the genetic variant on disease, i.e. = 0, and the protein can have any mixture of direct ( ), and indirect ( ) effects. For this reason, MR analysis of protein-disease relationships is less prone to violation of the 'no horizontal pleiotropy' assumption than MR analysis of downstream exposures.
Alternative exposures in cis-MR analysis of proteins
It is important to note that a protein can remain the inferential target in an MR analysis even if it is not measured directly. In the absence of available measures of the protein of interest, a similar argument can be made for using mRNA expression (this time as an upstream variable) that proxies the effect of genetic variation on the level of the encoded protein (see Appendix Figure 1 ):
Here the weighting is done by the association with of mRNA expression, and the effect has been decomposed into the variant effect on expression and the expression effect on protein level Similar as for , the expression weighted ("ew") drug target effect provides a valid test of = 0 conditional on the absence of any horizontal pleiotropy predicting the protein effect;
that is, a necessary assumption = = 0 (with index for expression). It should be noted that mRNA expression level (eQTL) is tissue-specific, and utilizing eQTLs for drug target MRs necessitates a decision on the tissue(s) relevant for (de novo) drug development. We return to these issues later in the manuscript.
Having provided the mathematical framework, we now address issues pertaining to the selection of instruments for cis-MR analysis of proteins. Specifically, we address locus selection (all protein-coding genes; genes only encoding druggable proteins); locus size; instrument selection (one versus many; selection based on LD or functionality); and potential influence of enhancer variants. Also, we illustrate the influence, and limitations, of weighting genetic instruments by mRNA expression vs. protein expression vs. level of some downstream biomarker, by starting with the current modus operandi in MR which is to weight instruments by a downstream biomarker exposure (which is often more widely measured than the protein of interest).
Throughout, we draw from current paradigms of MR analysis but critically extend and evaluate modelling choices to derive strategies most relevant for cis-MR.
Design, conduct and interpretation of cis-MR analysis of proteins encoding drug targets targeting mechanisms. However, currently, to define the druggable genome is to progressively reduce the high-dimensional search space for genetic instruments from the whole genome to around 20,000 protein coding genes to fewer than 5,000 genes encoding druggable targets. As such, a specific subset of cis-MR can inform drug development, which we term "drug target MR".
Instrument selection
Drug target MR focuses on a single gene known to encode a protein, and variants within and around such a gene are used to characterize the effect of the drug target on a single or multiple outcome(s). Given the inferential target, it would seem logical to select variants based on the variant to protein level association ( ). Ideally one would have sound knowledge on the number of causal variants and only select those to minimize bias and maximize precision (power).
However, typically this information is unavailable, imposing the need for instrument selection, often using biomarker risk factors as proxies for genetic effects on protein expression.
In such cases, variants are often selected based on 1) a biomarker association (e.g. LDL-C in the case of PCSK9 discussed earlier), 2) predicted functionality; and 3) low linkage disequilibrium (LD). These, often ad hoc, selection strategies typically result in the use of a single 24, 32, 33 or perhaps a handful of SNPs 22, 34, 35 out of a multitude of potential candidate SNPs.
Due to a lack of appropriate (pQTL or eQTL) data, it is often unclear how well such a small subset of SNPs characterizes the genetic effect on the drug target (IV assumption i), and how influential selection strategies are on the final MR estimate.
To explore this, we mimicked instrument selection by repeatedly (500 times) sampling four SNPs at random per locus 22,23 from four known drug target encoding loci HMGCR (statins), NPC1L1
(ezetimibe), PCSK9 (PCSK9 inhibitors), and CETP (CETP inhibitors). (In the next section we consider larger number of variants). These loci contain variants that influence LDL-cholesterol (HMGCR, NPC1L1, PCSK9, CETP), with variants at the CETP locus additionally influencing HDL-cholesterol and triglycerides as identified by the Global Lipids Genetics Consortium (GLGC 36 ). We then used a generalized least squares (GLS) method 12, 37 ; to account for pairwise LD between variants at each locus. Variants were extracted from within the gene ±2.5kb, with a minor allele frequency (MAF) above 0.01, and LD less than 0.80 (Appendix Tables 1-5, Appendix Figure 2 ).
The first and third quartiles (Q) of the CHD odds ratios (OR) per standard deviation (SD) in LDL-C for HMGCR, NPC1L1, PCSK9 (or HDL-C in the case of CETP) indicated modest variability in the point estimate: (Q1 1.61, Q3 1.78) for HMGCR, (Q1 1.42, Q3 1.77) for PCSK9, (Q1 1.19, Q3
1.68) for NPC1L1, and (Q1 0.87, Q3 0.91) for CETP. Between 95-99% of the estimates across all four genes were in the expected direction as inferred from the findings of drugs used in clinical trials to target the corresponding proteins [38] [39] [40] [41] [42] [43] [44] .
We further categorised effect estimates based on the EnsEMBL Variant Effect Prediction (VEP) that reports the functional consequence of each variant ( Figure 2 ). We found little to no difference between estimates derived using non-coding variants only and those estimates based on functional variants. The overall stability and agreement between estimates derived with or without functional annotations suggests a strong influence of multivariate LD between the selected and unselected variants in small cis-regions (Appendix Figure 2 ). However, we did observe a large degree of variability in the p-values which is explored in the subsequent section (Appendix Figure3).
Taking advantage of linkage disequilibrium within the region
Given the observed influence of LD it seems desirable to leverage this in drug target MR. For example, after defining a cis-genetic region (discussed further below) one can LD-clump highly correlated variants that might destabilize a statistical model (multicollinearity), and actively model the remaining pairwise LD using an LD-reference panel to maximize power and decrease variability. Besides increasing power and robustness, this strategy also introduces some further complexities e.g. the choice of LD threshold, and the ramification of the possible inclusion of null-variants (i.e. variants that are not associated with the risk-factor).
The effect of LD thresholds can be readily explored by performing a "grid search", clumping variants at different R-squared thresholds. From modelling theory, (and empirically: The possible inclusion of "null variants", that do not affect the intermediate risk factor, is more difficult to prevent. In a very conservative attempt at excluding null-variants researchers often focus on genome-wide significance (e.g., a p-value < 5 × 10 ). Dudbridge 45 and many others have shown that such an approach excludes many useful variants harming power/precision, and lower thresholds (e.g., 10 ) often result in greatly improved performance. Clearly such lower threshold could result in the inclusion of (many) null-variants. However, as sample size increases, null-variants will cluster around the origin when regressing the variant-outcome estimates on the variant-exposure estimates, and hence will not affect point estimates of the slope (see Appendix Figure 4 ). As such, null-variants are not expected to invalidate MR analyses if their inclusion is offset by other variants that are strong predictors of the risk factor; see Appendix Table 11 for a simulation study. Additionally, by employing the two-sample MR 46 paradigm (using risk factor and outcome estimates from different samples), any possible weakinstrument bias should attenuate results towards the null 47 .
Linkage disequilibrium modelling compared to selecting functional variants
Based on these considerations, we explored the performance of a very limited instrument selection strategy, geared towards characterizing a cis-genetic region encoding a drug target as fully as possible by: 1) considering all variants with limited LD clumping to prevent multicollinearity; 2) modelling LD using external data such as the 1000 genomes reference panel; 3) limited or no p-value thresholding. This strategy (with R 2 = 0.60) was applied to our four empirical examples and compared to MR estimates at the same locus using only variants with strong evidence of function based on VEP (Figure 4 and Appendix Tables 6-9). We found general agreement between the effect estimates from both analytical approaches, with the GLS estimates having higher precision (1/SE) than those based on functional variants alone. For example, the precision of the two PCSK9 splice variants used in MR was 5.72 compared to 13.33 for the GLS estimates (incorporating variants selected on the basis of LD structure regardless of function).
These results confirm that precision/power is increased by including more correlated variants. To prevent erroneously low p-values in such analyses, we accounted (conditioned) for pairwise LD used the European (EUR) 1000 genomes panel. We further investigated the influence of different 1000G ancestry reference panels on the effect estimates, and found these to be stable for the four examples evaluated (Appendix Figure 5 ); although significance of the NPC1L1 was dependent on the panel used. We did find however that the GLS method often failed because of (small) changes in LD resulting in multicollinearity. After inspection this seemed to be related to LD-estimates of low MAF variants varying considerably across ethnicities (Appendix Figure 6 ); improved behaviour may be expected with either increased sample size (1000G sample size n ~ 100), or with the removal of low MAF variants (at the risk of losing information).
Selection of the exposure (risk factor) to be instrumented
The analyses to this point have utilised lipids exposures to index the effect a drug on the corresponding target. With the publication of the INTERVAL study 8 , genetic associations with circulating protein concentration (pQTL data) have been made available for around 3,500
proteins measured using the Somalogic aptamer based chemistry in around 3,000 participants.
This opens up the possibility of using the genetic effect on protein concentration as a more direct proxy of the effect of a drug on its target. Of the four proteins considered here only HMGCR concentrations were available from the INTERVAL study. To supplement this we extracted pQTL estimates from a GWAS of circulating CETP concentration measured by an enzyme-linked immunosorbent assay (ELISA) 48 in around 4000 subjects. Initially focussing on the same ±2.5KB region as before, we found the causal estimates for the effect of HMGCR on CHD, using the Somalogic protein expression level to be very imprecise, failing to reject a null-effect ( Figure   5 ); despite the known beneficial effect of HMGCR inhibition by statin drugs on CHD risk.
Corresponding estimates using circulating CETP concentration based on an ELISA indicated a causal CHD increasing effect, consistent with the findings of a recent large-scale clinical trial where CETP inhibition reduces CHD risk ( Figure 5 ).
In the biomarker weighted analysis, the size of the genetic flanking region was constrained to prevent erroneously modelling effects from neighbouring genes not encoding the drug target of interest (horizontal pleiotropy). However, pQTL associations provide a direct estimate of the genetic association with the drug-target and hence reduces the need for small flaking regions.
We compared findings from the ±2.5KB region, to pQTL MR results using a broader ±1MB flanking region. To further guard against potential horizontal pleiotropy bias (for example through LD) we additionally implemented the Egger adjustment. At intermediate R 2 values (0.30),
HMGCR was significantly associated with an increased CHD risk (with Egger correction).
However, with larger values (R 2 = 0.50), the GLS failed, indicating model instability. Conversely, CETP was (again) robustly causally associated with CHD, with larger R-squared values decreasing variability without any indication of model instability ( Figure 5 ).
We additionally evaluated the performance of MR analysis using mRNA expression level as the exposure variable, assuming a certain proportionality between mRNA and protein expression.
We obtained information on genetic effects on mRNA expression from GTEx 49 version 7, for all four cis-regions, based on post mortem tissues from 449 donors (84% of European descent).
Variants were considered that were located in a ±1MB region around each gene. Relative expression levels for each gene differed considerably across tissues and between each locus (Appendix Figure 7 ). Most strikingly, HMGCR was uniformly expressed across tissues, while
CETP was most expressed in spleen, and PCKS9 and NPC1L1 in the liver. In Appendix Figures   8-11 we provide tissue-specific eQTL estimates over a number of genetic regions, showing that HMGCR eQTL variants were located throughout the surrounding ±1MB region, and that associations for the other loci were more confined: CETP (±10KB), PCSK9(±250KB), and NPC1L1 (±250KB). There was also considerable directional inconsistency in the effects of cisvariants on expression across the various tissues, for example NCP1L1 variants were negatively associated with expression in esophageal mucosa, with the same variants positively associated in aortic artery tissue (Appendix Figure 10 ).
This directional inconsistency resulted in directionally discordant tissue-specific MR estimates of the same drug-target. For example, PCSK9 mRNA expression in the adrenal gland was associated with an increase in CHD risk: OR 1.0.9 (95%CI 1.02; 1.16), while PCSK9 expression in the uterus was associated with decreased CHD risk: OR 0.92 (95%CI 0.88; 0.97). Selecting variants from a broader ±1MB region universally attenuated effect estimates, with Egger correction ( Figure 6 ) moderately reversing this attenuation. Horizontal pleiotropy did not however fully explain the directional inconsistency in CHD effects across tissues. For example, the causal relationship of HMGCR with CHD weighted based on instrument effects on HMGCR mRNA expression in brain regions (caudate basal ganglia, putamen basal ganglia, and spinal cord cervical c-1 tissues) using Egger correction would be inferred to be protective (opposite to that known to be the case from clinical trials).
Region size
To explore the possible cause of this directional inconsistency we next explored the influence of genetic region by iteratively increasing the flanking region from ±2.5KB to ±1MB, selecting variants from upstream, downstream or in both direction of the gene. With all 4 loci showing similar behaviour, we focus here on the CETP region (Figure 7 , see appendix Figures 12-14 for the other drug targets) finding that effect direction in any given tissue remained constant across the expanding region. The significance of the association with mRNA expression could either be attenuated when selecting variants from larger regions (e.g. lung tissue), or conversely increase, (e.g., spleen) potentially reflecting different regulatory regions including enhancers for the same gene in different tissues.
Statistical heterogeneity
To further explore the inconsistency in effect direction when weighting MR analysis by mRNA expression in different tissues, we estimated any potential causal relationship between mRNA expression level as the exposure and circulating lipid concentration (rather than CHD risk) as the outcome.
In these analyses, directional inconsistency was also observed (Appendix 15). However, comparing the mRNA expression level effect estimates on lipids, to the expression level estimates on CHD across tissues did not indicate a significant correlation between the two (Appendix 16;
correlation estimates between -0.20 and 0.20). As expected both the CHD and lipids estimates showed a large degree of heterogeneity (Appendix Figure 17 ), indicating either 1) remaining horizontal pleiotropy (despite Egger correction), or 2) true tissue specificity heterogeneity of the expression level effect on CHD. Excluding tissues or variants displaying greater heterogeneity, did not markedly decrease directional inconsistency of estimated causal effects using either lipids or CHD as outcomes (Appendix Figures 18-21 ).
Potential role of enhancer regions
Finally, to determine the influence of enhancer variants, we associated the number of tissue specific enhancers (extracted from HACER 50 ) to the MR results from the 4 positive control loci, which did not reveal any significant association (Appendix Figure 22 ). Additionally, we explored if the number of enhancers could be associated to the direction of effect (encoded as a binary indicator) which did not show a significant association either (Appendix Figure 22 ). In Figure 8 , we associated the tissue-specific heterogeneity statistics of the MR estimates to the distance to the nearest enhancer variants which again did not demonstrate a clear relationship.
Discussion
In the current manuscript we have formalised the difference between Mendelian randomization (MR) for biomarker validation and MR for drug target validation cis-region encoding a druggable protein. Using algebraic derivations, we show that because drug target MR considers the effects of perturbing a protein drug target on disease, this type of MR may be applied in settings where biomarker MR will be biased through horizontal pleiotropy. We discuss that because drug target MRs can be framed as a cis-focus analyses, instrument selection is distinct from that in generic MR, and investigate strategies characterizing the drug target encoding region as whole through linkage disequilibrium (LD), increasing precision and robustness. Simple grid-search algorithms were introduced aiding researcher in optimizing LD-threshold as well as genetic regions, with intuitive sensitivity analyses to determine estimate robustness to the choices of LD reference panel, the presence of functional variants as well as regulatory enhancers, and outliers (using heterogeneity statistics).
Due to our focus on four positive control examples, we were able to perform exhaustive analyses on the robustness of drug target MR findings based on regulatory vs coding variants showing that robust causal inferences could be drawn from regulatory variants despite a widely held view that functional variants should be naturally preferred in (drug target) MR analyses because most drugs affect protein action not level. Instead we showed that modelling an entire cis region resulted in the same odds ratio compared to selecting functional variants, with greater precision (increased power) by including larger numbers of (independent) variants. Similarly, we showed that limited influence of LD-reference panels used in LD modelling with non-European ancestry panels resulting in comparable estimates. While promising, these findings should be replicated and above all extended to a larger set of drug targets, for example to analyses outside of the lipids-cardiovascular domain presented.
In the current manuscript we pursued drug target Mendelian randomization by applying a generalized least squares (GLS) solution 51 to genetic cis-regions known to encode protein drug targets. This GLS method is by no means the only relevant estimator function and one can "repurpose" many general MR methods for use in drug target MR. For example, the MR-base platform clumps variants to such a low level (e.g., R-squared of 0.001) that one can apply weighted regression solutions (e.g., IVW), foregoing LD correction 13 . Generalised Summarydata-based Mendelian Randomisation (GSMR) 52 Throughout this manuscript we used a type I of error rate of 0.05 (or 95% confidence interval) and did not correct for multiple testing. While appropriate multiplicity protection is important, by focussing on four thoroughly studied drug targets (NPC1L1, HMGCR, PCSK9, and CETP) there is an abundance of prior evidence on the expected CHD effect, making analytical control of the false positive rate less relevant. In other settings, appropriate control of false discovery rates is clearly essential.it could be argued that applying a genome-wide association p-value threshold (e.g. 5 × 10 ) will be needlessly conservative. Instead, of applying the typical GWAS multiplicity correction one could control for the number of druggable proteins (about 5000;
resulting in a 1 × 10 threshold). However, (early) drug development is not performed in isolation, and genetic evidence will be evaluated alongside evidence from cells, tissues, and animal experiments. As such, appropriate false discovery control will depend on the position of drug target MR within this pre-existing evidence framework. For example, p-value threshold of 1 × 10 might be applied when drug target MR is used as a screening tool, before validating promising leads in further experiments. Positioning drug target MR after successful in-vivo experimentation, for example, to check for possible unknown side effects in human subjects, will likely call for a less-stringent multiplicity correction considering themore extensive prior knowledge and the aim of early detection of possible safety concerns.
In conclusion, we expect that combining the discussed concepts with the ever-increasing magnitude of genetic data will move drug target MR from manually curated, often proof of concept like analyses, to more automated and scalable projects able to systematically guide and enrich the entire drug development process.
Methods

Data resources
Information on the four positive control loci (HMGCR, PCSK9, CETP, and NPC1L1) were sourced from the Drug Target Validation Database (DTAdb), developed by Chris Finan 31 .
Specifically, for the current analyses we identified variants within a megabase upstream or downstream from each of the four loci. Outcome data were extracted from CARDIOGRAMplusC4D including the genetic association (log odds ratio) with CHD, as well as their standard errors. Exposure data were leveraged from GLGC 36 The 1000 genomes 56 data were used as a source of LD. Enhancer data were derived from the Human ACtive Enhancer to interpret Regular variants (HACER 50 ) resource. All information was curated and normalized to genetic build 37 as described in detail in Finan et al 31 . A ±2.5KB
subset of the data is provided in Appendix tables 1-4, with the remainder easily extracted from cited publicly available sources.
Statistical analysis
Mendelian randomization was conducted using the "Inverse Variance Weighted" (IVW) and "MR-Egger" methods for correlated variants as detailed in Burges et al 37 .
Here we note that these methods are specific parametrizations of Generalized Least Squares (GLS) technique and simply refer to IVW as GLS, and MR-Egger as GLS with Egger correction.
In or as random effects (where the regression standard error is equal or larger than 1).
All analyses were conducted using the R programming language 57 , with packages dplyr 58 , ggplot2 59 , gridExtra 60 , openxlsx 61 , and wesanderson 62 . Diagrams were programmed in TikZ 63 , and the appendix written in LaTeX and knitr 64 . Tables Table 1 Glossary Term Description
Figure legends
Confounder A common cause of both the exposure and outcome. Ignored confounding (measured or unmeasured) biases the exposure to outcome association.
Estimand
The parameter to be estimated. For example, the population mean
Estimate
The result of an estimator function. For example, the sample estimate ̂ Estimator A function that provides an estimate of an estimand. For example, an estimator of the population mean would be ∑ for measurements.
Exposure
A phenotype which may cause an outcome trait (disease state or risk factor). In the manuscript often refers to mRNA expression, protein, or biomarker levels.
Generalised least squares (GLS)
Generalised least squares is an extension of ordinary least squares (linear regression) to account for correlation between variants (due to LD). In the manuscript GLS refers to a linear model regressing the variant to outcome association on the variant to exposure association with the intercept forced through the origin. A GLS with Egger correction (see MR-Egger) refers to a similar linear model with the intercept is a free parameter.
Inverse variance weighted (IVW)
The IVW is an IV-estimator assuming an absence of directional pleiotropy. Can be implement using a GLS with the intercept forced through the origin.
Mendelian randomization
A study or principle that use genetic instrumental variables, often in a formal instrumental variable analysis. 
